Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock closed at $6.89 on 3/7/25 after a major increase of 10.8%. Moreover, this advance was accompanied by unusually high trading volume at 178% of normal. The stock has declined -17.5% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Karyopharm Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment